Effects of ethanol and haloperidol on plasma levels of hepatic enzymes, lipid profile, and apolipoprotein in rats.
This work studied the effects of ethanol in the absence and presence of haloperidol under two experimental conditions. In protocol 1, rats were treated daily with ethanol (4 g/kg, p.o.) for 7 days, and received only haloperidol (1 mg/kg, i.p.) from the 8th day to the 14th day. In protocol 2, animals received ethanol, and the treatment continued with ethanol and haloperidol from the 8th day to the 14th day. Results show increases in alanine transaminase (ALT; 48% and 55%) and aspartate transaminase (AST; 32% and 22%) levels after ethanol or haloperidol (14 days) treatments, as compared with controls. Apolipoprotein A-1 (APO A1) levels were increased by haloperidol, after 7- (148%) but not after 14-day treatments, as compared with controls. Levels of lipoprotein (high-density lipoprotein (HDL-C)) tended to be increased only by ethanol treatment for 14 days. ALT (80%) and AST (43%) levels were increased in the haloperidol plus ethanol group (protocol 2), as compared with controls. However, an increase in APO A1 levels was observed in the haloperidol group pretreated with ethanol (protocol 1), as compared with controls and ethanol 7-day treatments. Triglyceride (TG) levels were increased in the combination of ethanol and haloperidol in protocol 1 (234%) and 2 (106%), as compared with controls. Except for a small decrease in haloperidol groups, with or without ethanol, as related to ethanol alone, no other effect was observed in HDL-C levels. In conclusion, we showed that haloperidol might be effective in moderating lipid alterations caused by chronic alcohol intake.
Vasconcelos
S M M
SM
Department of Physiology and Pharmacology, Federal University of Ceará, Fortaleza, Brazil.
Pereira
R F
RF
Alves
R S
RS
Arruda Filho
A C V
AC
Aguiar
L M V
LM
Macedo
D S
DS
Freitas
R M
RM
Queiroz
M G R
MG
Sousa
F C F
FC
Viana
G S B
GS
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D016632:Apolipoprotein A-I / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D018492:Dopamine Antagonists / Q000494:pharmacology*; D000431:Ethanol / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D006220:Haloperidol / Q000494:pharmacology*; D008055:Lipids / Q000097:blood*; D008099:Liver / Q000187:drug effects* / Q000201:enzymology*; D008297:Male; D051381:Rats; D017208:Rats, Wistar
D016632:Apolipoprotein A-I; D018492:Dopamine Antagonists; D008055:Lipids; D000431:Ethanol; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D006220:Haloperidol